Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.65 |
| ▸ | TK2 | O00142 | 2/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.55 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.55 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10041235 | 1.00 | PYGM (0.65) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2585721 | 1.00 | PYGM (0.65) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13707489 | 1.00 | PYGM (0.65) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2582949 | 0.90 | PYGM (0.52) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL9134735 | 0.87 | TK2 (0.49) | PYGMTK2 | |
| SCHEMBL9134731 | 0.87 | TK2 (0.49) | PYGMTK2 | |
| SCHEMBL18513005 | 0.81 | PYGM (0.72) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL12173959 | 0.81 | PYGM (0.72) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6027506 | 0.81 | PYGM (0.72) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL14928850 | 0.81 | PYGM (0.72) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10736911-B2 | Use of a DHODH inhibitor in combination with an inhibitor of pyrimidine salvage | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-08-11 | — | — | US | claimed |
| US-10736911-B2 | Use of a DHODH inhibitor in combination with an inhibitor of pyrimidine salvage | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190209598-A1 | USE OF A DHODH INHIBITOR IN COMBINATION WITH AN INHIBITOR OF PYRIMIDINE SALVAGE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-07-11 | — | — | US | disclosed |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| WO-2017117006-A1 | USE OF A DHODH INHIBITOR IN COMBINATION WITH AN INHIBITOR OF PYRIMIDINE SALVAGE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2251015-B1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |
| US-5106951-A | Antineoplastic anthracyline agents intercalated with two aromatic side chains or an oligopeptide and covalently attached to an antibody | NEORX CORPORATION (US) | 1992-04-21 | — | — | US | disclosed |
| EP-0329184-A2 | Antimers and antimeric conjugation | NEORX CORPORATION (US) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209598-A1 | USE OF A DHODH INHIBITOR IN COMBINATION WITH AN INHIBITOR OF PYRIMIDINE SALVAGE | DHODH, DPYD, DHPS | PYGM 3219/4885TK2 123/4885SLC28A1 295/4885 |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | SLC29A1, PNP, SLC29A2 | PYGM 89/4885TK2 149/4885SLC28A1 14/4885 |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | PYGM 4/4885TK2 261/4885SLC28A1 104/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | PYGM 99/4885TK2 159/4885SLC28A1 8/4885 |
| US-10736911-B2 | Use of a DHODH inhibitor in combination with an inhibitor of pyrimidine salvage | DHODH, DPYD, DHPS | PYGM 3219/4885TK2 123/4885SLC28A1 295/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | PYGM 72/4885TK2 190/4885SLC28A1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.